These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 23629749)

  • 1. [Pharmacogenetics and antiepileptic drug metabolism: implication of genetic variants in cytochromes P450].
    Saldaña-Cruz AM; Sánchez-Corona J; Márquez de Santiago DA; García-Zapién AG; Flores-Martínez SE
    Rev Neurol; 2013 May; 56(9):471-9. PubMed ID: 23629749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic polymorphisms associated with antiepileptic metabolism.
    Lopez-Garcia MA; Feria-Romero IA; Fernando-Serrano H; Escalante-Santiago D; Grijalva I; Orozco-Suarez S
    Front Biosci (Elite Ed); 2014 Jun; 6(2):377-86. PubMed ID: 24896213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of pharmacogenetics in the metabolism of antiepileptic drugs: pharmacokinetic and therapeutic implications.
    Klotz U
    Clin Pharmacokinet; 2007; 46(4):271-9. PubMed ID: 17375979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacogenetics or "farm-ecogenetics"?].
    Gérard N; Elion J; Krishnamoorthy R
    J Soc Biol; 2000; 194(1):9-13. PubMed ID: 11107543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of the antiepileptic drugs phenytoin and lamotrigine.
    López M; Dorado P; Monroy N; Alonso ME; Jung-Cook H; Machín E; Peñas-Lledó E; Llerena A
    Drug Metabol Drug Interact; 2011; 26(1):5-12. PubMed ID: 21557672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical impact of pharmacogenetics on the treatment of epilepsy.
    Löscher W; Klotz U; Zimprich F; Schmidt D
    Epilepsia; 2009 Jan; 50(1):1-23. PubMed ID: 18627414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.
    Grover S; Gourie-Devi M; Baghel R; Sharma S; Bala K; Gupta M; Narayanasamy K; Varma B; Gupta M; Kaur K; Talwar P; Kaur H; Giddaluru S; Sharma A; Brahmachari SK; Indian Genome Variation Consortium ; Kukreti R
    Pharmacogenomics; 2010 Jul; 11(7):927-41. PubMed ID: 20602612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of polymorphisms of CYP2C9, CYP2C19, and ABCB1, and activity of P-glycoprotein with response to anti-epileptic drugs.
    Taur SR; Kulkarni NB; Gandhe PP; Thelma BK; Ravat SH; Gogtay NJ; Thatte UM
    J Postgrad Med; 2014; 60(3):265-9. PubMed ID: 25121365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pharmacogenetics].
    Hach I; Kirch W
    Praxis (Bern 1994); 2008 Oct; 97(21):1127-9. PubMed ID: 18951351
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenetics and enzyme induction/inhibition properties of antiepileptic drugs.
    Anderson GD
    Neurology; 2004 Nov; 63(10 Suppl 4):S3-8. PubMed ID: 15557548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response.
    Kirchheiner J; Nickchen K; Bauer M; Wong ML; Licinio J; Roots I; Brockmöller J
    Mol Psychiatry; 2004 May; 9(5):442-73. PubMed ID: 15037866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes.
    Kirchheiner J; Seeringer A
    Biochim Biophys Acta; 2007 Mar; 1770(3):489-94. PubMed ID: 17113714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polymorphic drug metabolism in anaesthesia.
    Restrepo JG; Garcia-Martín E; Martínez C; Agúndez JA
    Curr Drug Metab; 2009 Mar; 10(3):236-46. PubMed ID: 19442086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic factors associated with drug-resistance of epilepsy: relevance of stratification by patient age and aetiology of epilepsy.
    Sánchez MB; Herranz JL; Leno C; Arteaga R; Oterino A; Valdizán EM; Nicolás JM; Adín J; Armijo JA
    Seizure; 2010 Mar; 19(2):93-101. PubMed ID: 20064729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacogenetics and interindividual variability in drug response: cytochrome P-450 2C9 and coumarin anticoagulants].
    Becquemont L; Verstuyft C; Jaillon P
    Bull Acad Natl Med; 2006 Jan; 190(1):37-49; discussion 50-3. PubMed ID: 16878445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of CYP450 in pharmacokinetics and pharmacogenetics of antihypertensive drugs.
    Rodríguez Arcas MJ; García-Jiménez E; Martínez-Martínez F; Conesa-Zamora P
    Farm Hosp; 2011; 35(2):84-92. PubMed ID: 21093338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population estimation regarding the effects of cytochrome P450 2C19 and 3A5 polymorphisms on zonisamide clearance.
    Okada Y; Seo T; Ishitsu T; Wanibuchi A; Hashimoto N; Higa Y; Nakagawa K
    Ther Drug Monit; 2008 Aug; 30(4):540-3. PubMed ID: 18641551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs.
    Anderson GD
    Ther Drug Monit; 2008 Apr; 30(2):173-80. PubMed ID: 18367977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Personalized medicine for epilepsy based on the pharmacogenomic testing].
    Yoshida S; Sugawara T; Nishio T; Kaneko S
    Brain Nerve; 2011 Apr; 63(4):295-9. PubMed ID: 21441631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF; Liu JP; Chowbay B
    Drug Metab Rev; 2009; 41(2):89-295. PubMed ID: 19514967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.